Rezzayo
(Nemolizumab)ApprovedMonoclonal antibody
RocheNemolizumab is used to treat moderate to severe atopic dermatitis (eczema), a skin condition that causes intense itching and inflammation. It works by blocking a specific immune system protein that contributes to the disease.[2] Rezzayo is currently approved and in use across 13 indications[4].[1]
Rezzayo is one of 234 monoclonal antibody programs targeting Atopic Eczema. It is currently in Approved.
13
Indications
23
Total Trials
8
Active Trials
233
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Rezzayo
RocheApproved
Uloric
TakedaPreclinical
Glucotrol
PfizerPreclinical
Lorelco
SanofiPreclinical
Vemlidy
GileadPreclinical
Sovaldi
GileadPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Januvia
ZZydus Therapeutics Inc.
Preclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis10 trials
Show 7 more trials
Prurigo Nodularis4 trials
Systemic Sclerosis2 trials
Moderate to Severe Atopic Dermatitis2 trials
4 more indications
ESS1 trial
Pruritus1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Rezzayo drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Nemolizumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]